NCT04377815 (FORECAST) is a clinical trial of General Public cohort in COVID-19, sponsored by University College, London.

Who is sponsoring NCT04377815?

NCT04377815 is sponsored by University College, London.

What drugs are being tested in NCT04377815?

Interventions in NCT04377815: General Public cohort.

What condition does NCT04377815 study?

NCT04377815 studies COVID-19, Anosmia.

Is NCT04377815 still recruiting?

NCT04377815 is currently completed. Last updated 19 January 2021.

Last reviewed 2021-01-19 · How we verify

NCT04377815: FORECAST

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Finding Out if COVID-19 Infection Can be pREdicted by ChAnges in Smell and/or Taste

Completed Last updated 19 January 2021

What this trial tests

trial testing General Public cohort in COVID-19 in 569 participants. Completed in 24 June 2020.

Timeline

23 April 2020

Primary endpoint
14 May 2020

24 June 2020

Quick facts

Lead sponsor	University College, London
Status	Completed
Study type	OBSERVATIONAL
Enrollment	569
Start date	23 April 2020
Primary completion	14 May 2020
Estimated completion	24 June 2020
Sites	2 locations across United Kingdom

Drugs / interventions tested

General Public cohort

Conditions studied

COVID-19 — all drugs for COVID-19 →
Anosmia — all drugs for Anosmia →

Sponsor

University College, London

Who can join

18 and older, any sex, with COVID-19 or Anosmia. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The FORECAST Study is an observational cohort study looking at two cohorts of patients presenting with COVID-19: a general public cohort, aiming to investigate if new loss or reduced sense of smell and/or taste are early signs of COVID-19 and a hospital cohort, which will investigate if taste/smell changes can predict the clinical course of a COVID-19 infection.

Publications & conference data

5 peer-reviewed publications reference this trial (live from Europe PMC):

Seroprevalence of SARS-CoV-2 antibodies in people with an acute loss in their sense of smell and/or taste in a community-based population in London, UK: An observational cohort study.
Makaronidis J, Mok J, Balogun N, Magee CG, et al · · 2020 · cited 59× · PMID 33001967 · DOI 10.1371/journal.pmed.1003358
Distorted chemosensory perception and female sex associate with persistent smell and/or taste loss in people with SARS-CoV-2 antibodies: a community based cohort study investigating clinical course and resolution of acute smell and/or taste loss in people with and without SARS-Co
Makaronidis J, Firman C, Magee CG, Mok J, et al · · 2021 · cited 34× · PMID 33632171 · DOI 10.1186/s12879-021-05927-w
Aberrant olfactory network functional connectivity in people with olfactory dysfunction following COVID-19 infection: an exploratory, observational study.
Wingrove J, Makaronidis J, Prados F, Kanber B, et al · · 2023 · cited 30× · PMID 36883140 · DOI 10.1016/j.eclinm.2023.101883
SARS-Cov-2 Damage on the Nervous System and Mental Health.
Boulkrane MS, Ilina V, Melchakov R, Arisov M, et al · · 2022 · cited 4× · PMID 34191699 · DOI 10.2174/1570159x19666210629151303
Distorted chemosensory perception and female sex associate with persistent smell and/or taste loss in people with SARS-CoV-2 antibodies: A community based cohort study investigating clinical course and resolution of acute smell and/or taste loss in people with and without SARS-Co
Makaronidis J, Firman C, Magee C, Mok J, et al · · 2021 · DOI 10.21203/rs.3.rs-156677/v1

Verify or expand the search:

Other recruiting trials for COVID-19

Currently open trials in the same condition.

NCT07183709 — Safety and Immunogenicity Trial of PepGNP-COVID19 Vaccine in Adults · Phase 1 · active not recruiting
NCT07300839 — A Study to Learn About a COVID-19 Vaccine in Healthy Adults 50 Through 64 Years of Age · Phase 3 · active not recruiting
NCT07221162 — A Safety and Immunogenicity Trial of Boost-2867 Vaccine, Via Intranasal and Intramuscular Routes · Phase 1 · recruiting
NCT07215520 — Safety and Tolerability of a Newcastle Disease Virus-Based Mucosal COVID-19 Vaccine in Previously Vaccinated Adults · Phase 2 · recruiting
NCT07222384 — A Study to Learn About BNT162b2 (LP.8.1)-Adapted Vaccine Against SARS-CoV-2 in Children 5 Through 11 Years of Age That A · Phase 3 · active not recruiting

Other University College, London trials

Trials by the same sponsor.

NCT07386652 — Intensive Comprehensive Aphasia Programme for People With Post-Stroke Aphasia · NA · not yet recruiting
NCT06924086 — The Children's Adaptive Deep Brain Stimulation for Epilepsy Trial · NA · recruiting
NCT07386678 — Study of Imaging and Molecular Biomarkers in Uncomplicated Rhegmatogenous Retinal Detachment · not yet recruiting
NCT07414940 — ACTinium in Castrate-RESistant Prostate Cancer After LUTEtium · Phase 1, PHASE2 · not yet recruiting
NCT07214454 — TCDS for the Treatment of Chronic Migraine · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04377815 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University College, London
Last refreshed: 19 January 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04377815.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing